Cohort Profile: The Inflammatory Bowel Disease South Limburg Cohort (IBDSL)

Heuvel, Tim R A van den; Jonkers, Daisy; Jeuring, Steven; Romberg‐Camps, Mariëlle; Oostenbrug, Liekele E.; Zeegers, Maurice P.; Masclee, Ad; Pierik, Marie J.

doi:10.1093/ije/dyv088

Cited by 55 publications

(63 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A major strength of this study was the ability to assess cancer risk in a population‐based IBD cohort (gold standard), with over 93% patient completeness and thereby comprising the full disease spectrum from mild to severe cases. In view of the factors previously discussed, selection bias was unlikely . Second, the IBDSL cohort contains long‐term (since 1991) and detailed medical data (including medication data), which was derived by thorough manual exploration of all patient files.…”

Section: Discussionmentioning

confidence: 99%

“…All IBD patients from the population‐based IBD South Limburg cohort (IBDSL) were eligible for this study. The cohort has previously been described in detail . In brief, patients diagnosed with IBD between 1991 and 2011, while living in the well‐defined region of South Limburg and being over 18 years of age at diagnosis, were included and followed prospectively.…”

Section: Methodsmentioning

confidence: 99%

“…A multifaceted identification strategy, including hospitals, the nationwide Dutch pathology database (PALGA) and general practitioners, resulted in 93% completeness. As the remaining 7% was not likely to be associated with a certain IBD phenotype, an unselected population was assured. IBDSL has been approved by the Ethics Committee of the Maastricht University Medical Centre (NL31636.068.10), is registered in http://ClinicalTrial.gov (NCT02130349) and meets the ethical standards of the revised version of the declaration of Helsinki…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population‐based IBDSL cohort

Heuvel

Wintjens

Jeuring

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

The management of inflammatory bowel disease (IBD) has changed since the mid-1990s (e.g., use of thiopurines/anti-TNFα agents, improved surveillance programs), possibly affecting cancer risk. To establish current cancer risk in IBD, updates are warranted from cohorts covering this time span, and detailed enough to study associations with phenotype and medication. We studied intestinal-, extra-intestinal- and overall cancer risk in the Dutch population-based IBDSL cohort. In total, 1,157 Crohn's disease (CD) and 1,644 ulcerative colitis (UC) patients were diagnosed between 1991 and 2011, and followed until 2013. Standardized incidence ratios (SIRs) were calculated for CD and UC separately, as well as for gender-, phenotype-, disease duration-, diagnosis era- and medication groups. We found an increased risk for colorectal cancer in CD patients with colon involvement (SIR 2.97; 95% CI 1.08-6.46), but not in the total CD or UC population. In addition, CD patients were at increased risk for hematologic- (2.41; 1.04-4.76), overall skin- (1.55; 1.06-2.19), skin squamous cell- (SCC; 3.83; 1.83-7.04) and overall cancer (1.28; 1.01-1.60), whereas UC patients had no increased risk for extra-intestinal- and overall cancer. Finally, in a medication analysis on CD and UC together, long-term immunosuppression exposure (>12 months) was associated with an increased risk for hematologic cancer, non-Hodgkin lymphoma, SCC and overall cancer, and this increase was mainly attributed to thiopurines. IBD patients with long-term immunosuppression exposure can be considered as having a higher cancer risk, and our data support the advice in recent IBD guidelines to consider skin cancer screening in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population‐based IBDSL cohort

Heuvel

Wintjens

Jeuring

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…For detailed information on the IBDSL cohort, we refer to the cohort profile. 42 All patients with CD or UC present in the IBDSL registry were included. These patients were diagnosed between January 1, 1991 and December 31, 2010 (UC) and July 2011 (CD) at an age of 18 years or older.…”

Section: Study Populationmentioning

confidence: 99%

Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age—An Increasing Distinct Entity?

Jeuring

Heuvel

Zeegers

et al. 2016

Inflammatory Bowel Diseases

137

153

View full text Add to dashboard Cite

show abstract

“…The question is whether this trend changed significantly in the era of the anti-TNF antibodies. A recent study presented by Jeuring et al [26] from the Netherlands on a Dutch population-based cohort study in the south Limburg area [25] came to a disappointing result. The disease behavior of CD patients diagnosed in the biological era was not different to that diagnosed in the pre-biological era [26] .…”

Section: Introductionmentioning

confidence: 99%

Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-α Therapy: Pathophysiology and Clinical Implications

Rogler

Biedermann

Scharl

2017

Dig Dis

View full text Add to dashboard Cite

Cytokines are small proteins produced by a broad range of cells important in cell signaling. They include interleukins, but also chemokines, interferons, and tumor necrosis factors (TNF). They play an important role for communication between cells of the innate and adaptive immune system. The cytokine network is complex and, therefore, therapeutic interventions are difficult. The first anti-cytokine strategy successfully introduced into IBD therapy was the neutralization of TNF by antibodies. Beyond targeting this cytokine anti-IL-23 strategies were demonstrated to be of therapeutic benefit in IBD. Anti-IL-6 strategies seem to have clinical potential but also cause some risk for the patient due to the lack of CRP increase upon severe inflammation. JAK inhibitors target the intracellular signaling of several cytokine receptors and represent a promising class of broader and somewhat unspecific anti-cytokine strategies. Many other anti-cytokine approaches have failed due to the redundant nature of the cytokine network. Whether further anti-cytokines strategies have potential for IBD treatment may be evaluated in future studies.

show abstract

Cohort Profile: The Inflammatory Bowel Disease South Limburg Cohort (IBDSL)

Cited by 55 publications

References 61 publications

Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population‐based IBDSL cohort

Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population‐based IBDSL cohort

Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age—An Increasing Distinct Entity?

Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-α Therapy: Pathophysiology and Clinical Implications

Contact Info

Product

Resources

About